BioCentury | Oct 31, 2020
Deals

Oct. 30 Quick Takes: Q32 raises B round; plus CStone-LegoChem, Centrexion, Sidekick

Q32 raises $60M series B round, starts first clinical trialImmunology company Q32 Bio Inc. raised $60 million in a series B round led by OrbiMed Advisors and Acorn Bioventures, with participation from Osage University Partners, Atlas...
BioCentury | Feb 2, 2018
Company News

Partner Therapeutics raises $60M, in-licenses Leukine

Newco Partner Therapeutics Inc. (Boston, Mass.) raised $60 million on Feb. 1 in a series A round led by Perceptive Advisors and also gained rights to Leukine sargramostim from Sanofi (Euronext:SAN; NYSE:SNY). Fellow new investors...
BioCentury | Oct 26, 2015
Finance

Joining the in(novation) crowd

At least one buysider thinks the first two innovator Chinese biotechs to attempt a NASDAQ listing will be well-received by U.S. investors thanks to a combination of validating pharma deals and a stable of products...
BioCentury | Feb 25, 2013
Company News

Novation Holdings Inc., AVM Licensing Corp. deal

...sold its controlling interest in its medical device development subsidiary SureScreen Medical Inc. to AVM. Novation...
...notes in return and that the total value of the assets is estimated at $250,000. Novation...
...anticipated for further development of the technology. The companies could not be reached for details. Novation...
BioCentury | Jul 12, 2012
Targets & Mechanisms

More druggable than MYC

...offers a way around the druggability issue," said Dominique Cheneval, founder, president and COO of Novation Pharmaceuticals Inc....
...subunit 1 ( SAE1 ) and SAE2 ( UBA2 ) as potential druggable targets. 8 Novation...
...Mass. Fred Hutchinson Cancer Research Center , Seattle, Wash. GlaxoSmithKline plc. (LSE:GSK; NYSE:GSK), London, U.K. Novation Pharmaceuticals Inc....
BioCentury | Jul 2, 2012
Clinical News

Pradaxa: Additional Phase III data

Boehringer reported pooled data from the double-blind Phase III RE-MOBILIZE, RE-MODEL, RE-NOVATE and RE-NOVATE II trials in 10,148 patients showing that there was no significant difference between once-daily 150 or 220 mg Pradaxa and enoxaparin...
BioCentury | Jan 16, 2012
Clinical News

Pradaxa dabigatran etexilate cardiovascular data

Researchers at the Cleveland Clinic reported data from a meta-analysis of 30,514 subjects in 7 randomized controlled trials conducted by Boehringer showing that Pradaxa was associated with a significantly increased risk of MI or unstable...
BioCentury | Jun 14, 2010
Clinical News

Pradaxa dabigatran etexilate: Phase III data

In the double-blind Phase III RE-NOVATE II trial in 2,055 patients, Pradaxa was non-inferior to Lovenox enoxaparin on the composite primary endpoint of total venous thromboembolic events and all-cause mortality from days 28-35 after surgery...
BioCentury | Jun 12, 2010
Clinical News

Trial shows dabigatran non-inferior to Lovenox

Boehringer Ingelheim GmbH (Ingelheim, Germany) said dabigatran was non-inferior to Lovenox enoxaparin on the composite primary endpoint in the Phase III RE-NOVATE trial to prevent venous thromboembolism (VTE) following total hip replacement surgery. The direct...
BioCentury | Jun 22, 2009
Company News

Cancer Therapeutics CRC, Novation deal

...Pty. Ltd. , Bundoora, Australia Novation Pharmaceuticals Inc. , Vancouver, B.C. Business: Cancer The partners will combine Novation's...
...and SplA/ryanodine receptor domain and SOCS box containing 1 ( SPSB1 , SSB1 ). Novation...
...and Cancer Therapeutics will own compounds against SSB1. Further terms were not disclosed. In November, Novation...
Items per page:
1 - 10 of 15
BioCentury | Oct 31, 2020
Deals

Oct. 30 Quick Takes: Q32 raises B round; plus CStone-LegoChem, Centrexion, Sidekick

Q32 raises $60M series B round, starts first clinical trialImmunology company Q32 Bio Inc. raised $60 million in a series B round led by OrbiMed Advisors and Acorn Bioventures, with participation from Osage University Partners, Atlas...
BioCentury | Feb 2, 2018
Company News

Partner Therapeutics raises $60M, in-licenses Leukine

Newco Partner Therapeutics Inc. (Boston, Mass.) raised $60 million on Feb. 1 in a series A round led by Perceptive Advisors and also gained rights to Leukine sargramostim from Sanofi (Euronext:SAN; NYSE:SNY). Fellow new investors...
BioCentury | Oct 26, 2015
Finance

Joining the in(novation) crowd

At least one buysider thinks the first two innovator Chinese biotechs to attempt a NASDAQ listing will be well-received by U.S. investors thanks to a combination of validating pharma deals and a stable of products...
BioCentury | Feb 25, 2013
Company News

Novation Holdings Inc., AVM Licensing Corp. deal

...sold its controlling interest in its medical device development subsidiary SureScreen Medical Inc. to AVM. Novation...
...notes in return and that the total value of the assets is estimated at $250,000. Novation...
...anticipated for further development of the technology. The companies could not be reached for details. Novation...
BioCentury | Jul 12, 2012
Targets & Mechanisms

More druggable than MYC

...offers a way around the druggability issue," said Dominique Cheneval, founder, president and COO of Novation Pharmaceuticals Inc....
...subunit 1 ( SAE1 ) and SAE2 ( UBA2 ) as potential druggable targets. 8 Novation...
...Mass. Fred Hutchinson Cancer Research Center , Seattle, Wash. GlaxoSmithKline plc. (LSE:GSK; NYSE:GSK), London, U.K. Novation Pharmaceuticals Inc....
BioCentury | Jul 2, 2012
Clinical News

Pradaxa: Additional Phase III data

Boehringer reported pooled data from the double-blind Phase III RE-MOBILIZE, RE-MODEL, RE-NOVATE and RE-NOVATE II trials in 10,148 patients showing that there was no significant difference between once-daily 150 or 220 mg Pradaxa and enoxaparin...
BioCentury | Jan 16, 2012
Clinical News

Pradaxa dabigatran etexilate cardiovascular data

Researchers at the Cleveland Clinic reported data from a meta-analysis of 30,514 subjects in 7 randomized controlled trials conducted by Boehringer showing that Pradaxa was associated with a significantly increased risk of MI or unstable...
BioCentury | Jun 14, 2010
Clinical News

Pradaxa dabigatran etexilate: Phase III data

In the double-blind Phase III RE-NOVATE II trial in 2,055 patients, Pradaxa was non-inferior to Lovenox enoxaparin on the composite primary endpoint of total venous thromboembolic events and all-cause mortality from days 28-35 after surgery...
BioCentury | Jun 12, 2010
Clinical News

Trial shows dabigatran non-inferior to Lovenox

Boehringer Ingelheim GmbH (Ingelheim, Germany) said dabigatran was non-inferior to Lovenox enoxaparin on the composite primary endpoint in the Phase III RE-NOVATE trial to prevent venous thromboembolism (VTE) following total hip replacement surgery. The direct...
BioCentury | Jun 22, 2009
Company News

Cancer Therapeutics CRC, Novation deal

...Pty. Ltd. , Bundoora, Australia Novation Pharmaceuticals Inc. , Vancouver, B.C. Business: Cancer The partners will combine Novation's...
...and SplA/ryanodine receptor domain and SOCS box containing 1 ( SPSB1 , SSB1 ). Novation...
...and Cancer Therapeutics will own compounds against SSB1. Further terms were not disclosed. In November, Novation...
Items per page:
1 - 10 of 15